2025-06-05-Jefferies-爱若优科技（ALUR）_帝国心态_为2026年美国推出铺平道路；美国以外地区程序稳定_8页_107kb

Allurion Technologies (ALUR) Equity Research Summary

Overall Recommendation: Buy with a price target of $18.00, implying a potential 529% upside from the current price of $2.86. Jefferies maintains a strong rating based on progress in US FDA approval and product performance.

Key Highlights

• US Launch: Allurion is on track to submit the final PMA module by end of June 2025, paving the way for a potential launch in 2026. The FDA has expressed receptiveness to alternative data analysis methods, which could improve the likelihood of approval by providing a more accurate representation of control group performance.
• Data Analysis De-Risking: Innovative statistical methods may address the narrow 3% superiority margin missed in the AUDACITY trial, potentially supporting approval despite initial setbacks.
• Financials: The company guides FY2025 sales at $30MM and has a cash runway sufficient for FDA approval, profitability, and other milestones. A workforce reduction of 50% has been implemented to realign with strategic priorities, supported by ~$20MM in cash.
• OUS Procedures and Data: Ongoing operations in markets outside the US remain stable, with positive trial data demonstrating significant weight loss and muscle mass gains from the ALUR Balloon and Virtual Care Suite. Outcomes in real-world settings show high success rates in weight reduction and improved body composition.
• Clinical Data: Recent abstracts highlight strong weight loss results (e.g., >14% reduction in OUS RW experience) and efficacy of the Virtual Care Suite when combined with other treatments.
• Risks: Despite the Buy rating, major risks include US approval uncertainty, GLP-1 competition, regulatory delays, and reimbursement challenges. Jefferies' valuation assumes 3x FY2026 sales, but execution risks could impact timelines and financial projections.

Analyst Commentary

• Jefferies analysts emphasize the potential for the VCS and balloon to outperform in real-world use cases, reinforcing the upside scenario. However, ongoing FDA feedback and competition remain critical factors for investors.